Quality Indicators in Cranial Neurosurgery: Which Are Presently Substantiated? A Systematic Review

Stephanie Schipmann(University of Bergen), Walter Stummer(University of Münster), Nils Warneke, N. Roeder(GEO Partner (Switzerland)), Wolf-Ingo Steudel(University Medical Center), Michael Schwake(University Hospital Münster), Eric Suero Molina

World Neurosurgery

April 29, 2017

10.1016/j.wneu.2017.03.111

Cited by 29

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

|Neurosurgery|2015|368